Pembrolizumab Activity in BCG-Refractory Papillary Bladder Cancer Pembrolizumab Activity in BCG-Refractory Papillary Bladder Cancer

Pembrolizumab monotherapy showed promising antitumor activity for patients with high-risk non –muscle invasive bladder cancer that did not respond to standard treatment with BCG.Medscape Medical News
Source: Medscape Transplantation Headlines - Category: Transplant Surgery Tags: Hematology-Oncology News Source Type: news